

# CITATION REPORT

List of articles citing

**Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer**

**DOI: 10.18632/oncotarget.23315**  
**Oncotarget, 2018, 9, 4375-4384.**

**Source:** <https://exaly.com/paper-pdf/87793375/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
21	Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody. <i>Cancer Biology and Therapy</i> , <b>2019</b> , 20, 109-121	4.6	13
20	Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?. <i>Cancers</i> , <b>2019</b> , 11,	6.6	17
19	BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma. <i>Journal of Translational Medicine</i> , <b>2019</b> , 17, 386	8.5	17
18	Identification of genes associated with cancer progression and prognosis in lung adenocarcinoma: Analyses based on microarray from Oncomine and The Cancer Genome Atlas databases. <i>Molecular Genetics &amp; Genomic Medicine</i> , <b>2019</b> , 7, e00528	2.3	32
17	Positive feedback loop of lncRNA LINC01296/miR-598/Twist1 promotes non-small cell lung cancer tumorigenesis. <i>Journal of Cellular Physiology</i> , <b>2019</b> , 234, 4563-4571	7	27
16	Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920937902	5.4	13
15	Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 582884	5.3	11
14	Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2020</b> , 108, 17-26	4	8
13	Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure. <i>Cancers</i> , <b>2020</b> , 12,	6.6	11
12	The B7-H4 gene induces immune escape partly via upregulating the PD-1/Stat3 pathway in non-small cell lung cancer. <i>Human Immunology</i> , <b>2020</b> , 81, 254-261	2.3	3
11	Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLR4-dependent antitumor immunity. <b>2021</b> , 9,		1
10	Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients. <i>Scientific Reports</i> , <b>2021</b> , 11, 2514	4.9	1
9	Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 662236	5.3	6
8	Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 693609	8.4	4
7	Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cells.		1
6	The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	4
5	Immune Therapy: What Can We Learn From Acquired Resistance?. <i>Current Cancer Research</i> , <b>2021</b> , 75-114.	0.2	

4	Discovery of biomarkers of resistance to immune checkpoint blockade in non-small-cell lung cancer (NSCLC) using high-plex digital spatial profiling.. <i>Journal of Thoracic Oncology</i> , <b>2022</b> ,	8.9	0
3	The oligometastatic spectrum in the era of improved detection and modern systemic therapy. <i>Nature Reviews Clinical Oncology</i> ,	19.4	1
2	Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab.		1
1	Post-progression survival in advanced non-small cell lung cancer treated with anti-PD-1/PDL-1 monotherapy: progression after durable clinical benefit versus primary resistance.		0